Datopotamab Deruxtecan vs Sacituzumab Tirumotecan

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Non-Small Cell Lung Cancer

Shared mechanism: TROP2 · full Non-Small Cell Lung Cancer pipeline

Datopotamab Deruxtecan

Marketed by Daiichi Sankyo and partners

Approved in Non-Small Cell Lung Cancerantibody-drug conjugate
Partial signal

NCT04656652 · Phase 3 · active, not recruiting

This open-label, randomized Phase III trial (TROPION-Lung01) assigned 604 patients with previously treated advanced or metastatic non-small cell lung cancer to datopotamab deruxtecan or docetaxel. It had two primary endpoints, progression-free survival and overall survival. Progression-free survival improved significantly (hazard ratio 0.75, P=.004), but overall survival showed only a numerical benefit that did not reach statistical significance (hazard ratio 0.94, P=.530). One primary was met and one was missed, so the result is mixed. Source: the peer-reviewed paper (Ahn et al., J Clin Oncol 2025).

Next expected readout: January 2027 · NCT06417814 (registry estimate)

Reported efficacy

Progression-free Survival (PFS) As Assessed by Blinded Independent Central Review (BICR) Per RECIST v1.1 Following DS-1062a Versus Docetaxel (From randomization until disease progression or death (whichever occurs first), up to approximately 27 months); Overall Survival (OS) Following DS-1062a Versus Docetaxel (From randomization until date of death due to any cause, up to to approximately 38 months): Dual primaries vs docetaxel: progression-free survival 4.4 vs 3.7 months (hazard ratio 0.75; 95% CI 0.62 to 0.91; P=.004); overall survival 12.9 vs 11.8 months (hazard ratio 0.94; 95% CI 0.78 to 1.14; P=.530) (TROPION-Lung01, J Clin Oncol 2025). (mixed)

Result source: NCT04656652

Sacituzumab Tirumotecan

Marketed by Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. and partners

Phase 3 in Non-Small Cell Lung Cancerantibody-drug conjugate
Partial signal

NCT05870319 · Phase 3 · active, not recruiting

This is a randomized, adequately sized (n=376) trial with an active comparator (standard chemotherapy) and a hard clinical endpoint (progression-free survival), and the result was strongly positive favoring the drug. However, the study was conducted open-label with no blinding, which limits confidence in a design that would otherwise support a top-tier grade despite the clear and statistically robust result.

Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.

Next expected readout: November 2026 · NCT06448312 (registry estimate)

Reported efficacy

Progression-free survival (PFS) (From baseline until disease progression, death, or other protocol defined reason,up to approximately 36 months): OptiTROP-Lung04 (NCT05870319), primary endpoint median PFS: sacituzumab tirumotecan 8.3 months vs chemotherapy 4.3 months; HR 0.49; p<0.0001 (met)

Result source: NCT05870319

Results for Non-Small Cell Lung Cancer

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointDatopotamab DeruxtecanSacituzumab Tirumotecan
PFS, median4.4 vs 3.7vs Docetaxel6.0 mg/kg · n 299NCT04656652
1 other result
  • 4.4 vs 3 6.0 mg/kg · n 299 · Phase 3 · secondary NCT04656652
—Trial running · NCT05870319
OS, median12.9 vs 11.8vs Docetaxel6.0 mg/kg · n 299NCT04656652—Trial running · NCT05870319
ORR35.8%b6.0 mg/kg Q3W · n 137NCT04484142—Trial running · NCT05870319
Duration of response, median—Trial running · NCT04656652—Trial running · NCT05870319

PFS, median

Datopotamab Deruxtecan
4.4 vs 3.7vs Docetaxel6.0 mg/kg · n 299NCT04656652
1 other result
  • 4.4 vs 3 6.0 mg/kg · n 299 · Phase 3 · secondary NCT04656652
Sacituzumab Tirumotecan
—Trial running · NCT05870319

OS, median

Datopotamab Deruxtecan
12.9 vs 11.8vs Docetaxel6.0 mg/kg · n 299NCT04656652
Sacituzumab Tirumotecan
—Trial running · NCT05870319

ORR

Datopotamab Deruxtecan
35.8%b6.0 mg/kg Q3W · n 137NCT04484142
Sacituzumab Tirumotecan
—Trial running · NCT05870319

Duration of response, median

Datopotamab Deruxtecan
—Trial running · NCT04656652
Sacituzumab Tirumotecan
—Trial running · NCT05870319
  1. b Single-arm result: the trial had no control arm, so the number has no comparator and does not compare with a randomised result.
  2. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  3. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.

Sacituzumab Tirumotecan
OptiTROP-Lung04 (NCT05870319), primary endpoint median PFS: sacituzumab tirumotecan 8.3 months vs chemotherapy 4.3 months; HR 0.49; p<0.0001 NCT05870319 · Phase 3 · design grade: moderate · publication or press release

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. Datopotamab Deruxtecan: 4 of 4 rows · Sacituzumab Tirumotecan: 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricDatopotamab Deruxtecan
Dropout rate
77.3%6.0 mg/kga
NCT04656652 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
show 1 more result
85.4%6.0 mg/kg Q3W
NCT04484142 · Phase 2
Discontinued due to AEs
—6.0 mg/kga
NCT04656652 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
show 1 more result
9.5%6.0 mg/kg Q3W
NCT04484142 · Phase 2
Serious AEs
31%6.0 mg/kga
NCT04656652 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
show 1 more result
24.8%6.0 mg/kg Q3W
NCT04484142 · Phase 2
Most frequent reported AEs
6.0 mg/kga
stomatitis 49.8%
nausea 37.7%
alopecia 32%
NCT04656652 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
show 1 more result
6.0 mg/kg Q3W
nausea 59.9%
stomatitis 57.7%
alopecia 51.1%
NCT04484142 · Phase 2

Notes

  1. aPopulation comparability has not been reviewed for 1 of these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Datopotamab Deruxtecan

PFS 4.4 vs 3.7 Docetaxel months6.0 mg/kg
time to event · months
NCT04656652 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
show 1 more result
4.4 vs 3 Docetaxel months6.0 mg/kg
NCT04656652 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
Overall Survival 12.9 vs 11.8 Docetaxel months6.0 mg/kg
time to event · months
NCT04656652 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
ORR 26.4% (n=299) vs 12.8% (n=305) Docetaxel6.0 mg/kg
event count · % of participants
Assessed by Blinded Independent Central Review
NCT04656652 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3 · converted to % from 79 Participants as posted
Duration of Response 7.1 vs 5.6 Docetaxel months6.0 mg/kg
time to event · months
Assessed by Blinded Independent Central Review
NCT04656652 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
ORR 35.8% (n=137)6.0 mg/kg Q3W
responder rate · % of participants
No placebo or comparator arm
NCT04484142 · Phase 2

HR+/HER2- Metastatic Breast Cancer

Shared mechanism: TROP2 · full HR+/HER2- Metastatic Breast Cancer pipeline

Datopotamab Deruxtecan

Marketed by Daiichi Sankyo and partners

Approved in HR+/HER2- Metastatic Breast Cancerantibody-drug conjugate
Partial signal

NCT05104866 · Phase 3 · active, not recruiting

Patients were randomized (365 vs 367) against active chemotherapy, but the study was open-label with no masking. The two co-primary endpoints disagreed: progression-free survival was significantly better (hazard ratio 0.63, p<0.0001) while overall survival showed no difference (hazard ratio 1.01, p=0.9445).

Next expected readout: May 2027 · NCT04644068 (registry estimate)

Reported efficacy

Progression-Free Survival (On-study tumor assessments occur every 6 weeks then every 9 weeks until disease progression, death or withdrawal of consent assessed up to data cut-off (17Jul2023) to a maximum of approximately 21 months); Overall Survival (From date of randomization until death due to any cause. Assessed up to data cut-off (24Jul2024) to a maximum of approximately 33 months.): Progression-Free Survival (On-study tumor assessments occur every 6 weeks then every 9 weeks until disease progression, death or withdrawal of consent assessed up to data cut-off (17Jul2023) to a maximum of approximately 21 months): Dato-DXd 6.9 Months (95% CI 5.7 to 7.4) vs Investigator's Choice of Chemotherapy (ICC) 4.9 Months (95% CI 4.2 to 5.5) (mixed)

Result source: NCT05104866

Sacituzumab Tirumotecan

Marketed by Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. and partners

Phase 3 in HR+/HER2- Metastatic Breast Cancerantibody-drug conjugate
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

Next expected readout: December 2026 · NCT06081959 (registry estimate)

No aligned efficacy figure on record for this race.

Results for HR+/HER2- Metastatic Breast Cancer

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointDatopotamab DeruxtecanSacituzumab Tirumotecan
PFS, median6.9 vs 4.9vs Investigator's Choice of Chemotherapy (ICC)n 365NCT05104866
1 other result
—Trial running · NCT06312176
OS, median18.6 vs 18.3vs Investigator's Choice of Chemotherapy (ICC)n 365NCT05104866—Trial running · NCT06312176
ORR—Trial running · NCT05104866—Trial running · NCT06312176
Clinical benefit rate—Trial running · NCT05104866—Trial running · NCT06312176

PFS, median

Datopotamab Deruxtecan
6.9 vs 4.9vs Investigator's Choice of Chemotherapy (ICC)n 365NCT05104866
1 other result
Sacituzumab Tirumotecan
—Trial running · NCT06312176

OS, median

Datopotamab Deruxtecan
18.6 vs 18.3vs Investigator's Choice of Chemotherapy (ICC)n 365NCT05104866
Sacituzumab Tirumotecan
—Trial running · NCT06312176

ORR

Datopotamab Deruxtecan
—Trial running · NCT05104866
Sacituzumab Tirumotecan
—Trial running · NCT06312176

Clinical benefit rate

Datopotamab Deruxtecan
—Trial running · NCT05104866
Sacituzumab Tirumotecan
—Trial running · NCT06312176
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Sacituzumab Tirumotecan: no structured comparison results are available for HR+/HER2- Metastatic Breast Cancer.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. Datopotamab Deruxtecan: 2 of 4 rows · Sacituzumab Tirumotecan: 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricDatopotamab Deruxtecan
Dropout rate
n/a: no completion milestone
NCT05104866 · Phase 3 · monotherapy · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
Discontinued due to AEs
—
NCT05104866 · Phase 3 · monotherapy · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
Serious AEs
17.2%
NCT05104866 · Phase 3 · monotherapy · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
Most frequent reported AEs
nausea 56.7%
stomatitis 52.2%
alopecia 37.8%
NCT05104866 · Phase 3 · monotherapy · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Datopotamab Deruxtecan

PFS 6.9 vs 4.9 Investigator's Choice of Chemotherapy (ICC) months
time to event · months
NCT05104866 · Phase 3 · monotherapy · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
show 1 more result
6.9 vs 4.5 Investigator's Choice of Chemotherapy (ICC) months
NCT05104866 · Phase 3 · monotherapy · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
Overall Survival 18.6 vs 18.3 Investigator's Choice of Chemotherapy (ICC) months
time to event · months
NCT05104866 · Phase 3 · monotherapy · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
ORR 36.44% (n=365) vs 22.89% (n=367) Investigator's Choice of Chemotherapy (ICC)
responder rate · % of participants
Confirmed response by BICR assessment based on IA1 data cut-off Raw Response Rate (%)
NCT05104866 · Phase 3 · monotherapy · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
Duration of Response 6.7 vs 5.7 Investigator's Choice of Chemotherapy (ICC) months
time to event · months
NCT05104866 · Phase 3 · monotherapy · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
show 1 more result
7.2 vs 6 Investigator's Choice of Chemotherapy (ICC) months
NCT05104866 · Phase 3 · monotherapy · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3

Breast Cancer

Shared mechanism: TROP2 · full Breast Cancer pipeline

Datopotamab Deruxtecan

Marketed by Daiichi Sankyo and partners

Approved in Breast Cancerantibody-drug conjugate
Partial signal

NCT05104866 · Phase 3 · active, not recruiting

Patients were randomized (365 vs 367) against active chemotherapy, but the study was open-label with no masking. The two co-primary endpoints disagreed: progression-free survival was significantly better (hazard ratio 0.63, p<0.0001) while overall survival showed no difference (hazard ratio 1.01, p=0.9445).

Next expected readout: May 2027 · NCT04644068 (registry estimate)

Reported efficacy

Progression-Free Survival (On-study tumor assessments occur every 6 weeks then every 9 weeks until disease progression, death or withdrawal of consent assessed up to data cut-off (17Jul2023) to a maximum of approximately 21 months); Overall Survival (From date of randomization until death due to any cause. Assessed up to data cut-off (24Jul2024) to a maximum of approximately 33 months.): Progression-Free Survival (On-study tumor assessments occur every 6 weeks then every 9 weeks until disease progression, death or withdrawal of consent assessed up to data cut-off (17Jul2023) to a maximum of approximately 21 months): Dato-DXd 6.9 Months (95% CI 5.7 to 7.4) vs Investigator's Choice of Chemotherapy (ICC) 4.9 Months (95% CI 4.2 to 5.5) (mixed)

Result source: NCT05104866

Sacituzumab Tirumotecan

Marketed by Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. and partners

Phase 3 in Breast Cancerantibody-drug conjugate
Partial signal

NCT05347134 · Phase 3 · active, not recruiting

This was a randomized, adequately sized (n=254) phase 3 trial with an active chemotherapy comparator and a hard clinical endpoint (progression-free survival, reviewed independently), and it clearly succeeded, showing a large PFS benefit for sac-TMT over chemotherapy. However, the trial was open-label with no blinding of patients or investigators, which limits confidence in any endpoints subject to subjective influence, so despite the strong result this design element keeps the grade at moderate rather than the highest tier.

Next expected readout: December 2026 · NCT06081959 (registry estimate)

Reported efficacy

Progression-free survival (PFS) (up to 24 months): OptiTROP-Breast01 (NCT05347134), primary endpoint median PFS: sac-TMT 6.7 months vs chemotherapy 2.5 months; HR 0.32 (95% CI 0.24-0.44); p<0.00001 (met)

Result source: NCT05347134

Results for Breast Cancer

There are not yet structured results for two selected drugs in this indication. Available results are listed below instead of an empty comparison table.

Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.

Sacituzumab Tirumotecan
OptiTROP-Breast01 (NCT05347134), primary endpoint median PFS: sac-TMT 6.7 months vs chemotherapy 2.5 months; HR 0.32 (95% CI 0.24-0.44); p<0.00001 NCT05347134 · Phase 3 · design grade: moderate · publication or press release

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Datopotamab Deruxtecan

PFS 6.9 vs 4.9 Investigator's Choice of Chemotherapy (ICC) months
time to event · months
NCT05104866 · Phase 3 · monotherapy · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
show 1 more result
6.9 vs 4.5 Investigator's Choice of Chemotherapy (ICC) months
NCT05104866 · Phase 3 · monotherapy · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
Overall Survival 18.6 vs 18.3 Investigator's Choice of Chemotherapy (ICC) months
time to event · months
NCT05104866 · Phase 3 · monotherapy · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
ORR 36.44% (n=365) vs 22.89% (n=367) Investigator's Choice of Chemotherapy (ICC)
responder rate · % of participants
Confirmed response by BICR assessment based on IA1 data cut-off Raw Response Rate (%)
NCT05104866 · Phase 3 · monotherapy · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
Duration of Response 6.7 vs 5.7 Investigator's Choice of Chemotherapy (ICC) months
time to event · months
NCT05104866 · Phase 3 · monotherapy · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
show 1 more result
7.2 vs 6 Investigator's Choice of Chemotherapy (ICC) months
NCT05104866 · Phase 3 · monotherapy · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
Available safety results

Datopotamab Deruxtecan

Dropout rate
n/a: no completion milestone
NCT05104866 · Phase 3 · monotherapy · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
Discontinued due to AEs
—
NCT05104866 · Phase 3 · monotherapy · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
Serious AEs
17.2%
NCT05104866 · Phase 3 · monotherapy · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
Most frequent reported AEs
nausea 56.7%
stomatitis 52.2%
alopecia 37.8%
NCT05104866 · Phase 3 · monotherapy · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Datopotamab Deruxtecan's landscape · Sacituzumab Tirumotecan's landscape